Hinova Pharmaceuticals (SHA:688302) secured approval from the China National Drug Administration to conduct clinical trials of HP568 tablets for the treatment of advanced breast cancer.
The drug is indicated for the treatment of estrogen receptor positive and human epidermal growth factor receptor 2 negative advanced breast cancer, according to a Wednesday filing with the Shanghai bourse.
Hinova Pharmaceuticals shares rose 2% in recent trade.
Price (RMB): ¥32.73, Change: ¥+0.53, Percent Change: +1.65%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.